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Abstract Somatic mutations in the estrogen receptor alpha (ERa) gene (ESR1), especially Y537S
and D538G, have been linked to acquired resistance to endocrine therapies. Cell-based studies
demonstrated that these mutants confer ERa constitutive activity and antiestrogen resistance and
suggest that ligand-binding domain dysfunction leads to endocrine therapy resistance. Here, we
integrate biophysical and structural biology data to reveal how these mutations lead to a
constitutively active and antiestrogen-resistant ERa. We show that these mutant ERs recruit
coactivator in the absence of hormone while their affinities for estrogen agonist (estradiol) and
antagonist (4-hydroxytamoxifen) are reduced. Further, they confer antiestrogen resistance by
altering the conformational dynamics of the loop connecting Helix 11 and Helix 12 in the ligand-
binding domain of ERa, which leads to a stabilized agonist state and an altered antagonist state
that resists inhibition.
DOI: 10.7554/eLife.12792.001
Introduction
The estrogen receptor a (ERa) is a ligand-activated nuclear hormone receptor and a major regulator
of cell growth, survival, and metastasis in a large fraction of breast cancers. Inhibiting the action of
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ERa with selective estrogen receptor modulators (SERMs) or selective estrogen receptor degraders
(SERDs), or reducing endogenous estrogen levels with aromatase inhibitors (AI), are effective treat-
ments for many of these breast cancers (Strasser-Weippl and Goss, 2005). Due to their efficacy and
broad therapeutic indices, antiestrogens can be administered sequentially for progressive disease
over the course of several years (Toy et al., 2013). Unfortunately, despite continued expression of
ERa, the majority of metastatic breast cancers that initially respond to endocrine therapies become
refractory.
Recently, somatic mutations in the ERa gene (ESR1) were linked to acquired resistance to endo-
crine therapies of breast cancer (Toy et al., 2013; Merenbakh-Lamin et al., 2013; Robinson et al.,
2013; Li et al., 2014; Jeselsohn et al., 2014). Approximately 25% of patients who previously
received SERM/SERD/AI treatments for an average of five years presented with conserved somatic
mutations that were not identified in primary (untreated) tumors. The most prevalent ERa point
mutations were Y537S and D538G, while several others were identified at significantly reduced fre-
quencies. Importantly, breast cancer cell-based studies revealed that the Y537S and D538G muta-
tions conferred hormone-independent activation of ERa and reduced the inhibitory potency and
efficacy of clinically prescribed SERMs and SERDs (Toy et al., 2013; Merenbakh-Lamin et al., 2013;
Robinson et al., 2013; Li et al., 2014; Jeselsohn et al., 2014; Carlson et al., 1997). Notably, the
constitutive activity and antagonist resistance of the Y537S and E380Q mutations were first
described in cell models in 1996 (Weis et al.,1996), and shortly thereafter, the Y537N mutation was
found in a clinical sample of metastatic breast cancer (Zhang et al., 1997). However, no clinical fol-
low-up studies were reported until 2013.
The Y537S and D538G mutations are especially interesting because they occur at the N-terminus
of Helix 12 (H12) in the ERa ligand-binding domain (LBD). Structurally, ERa LBD is an a-helical bun-
dle, with the C-terminal helix, H12, functioning as a key structural component of the activating
eLife digest Around one in every eight women will be diagnosed with breast cancer in their
lifetime. Hormone-based therapies – also referred to antiestrogen drugs – target a protein called
estrogen receptor alpha and are effective treatments for the majority of these cancers.
Unfortunately, about half of patients will develop recurrent breast cancers even though the cancer
continues to produce the target of the drugs.
The estrogen receptor alpha drives breast cancer in a number of ways, many of which require the
receptor to be activated by binding to the hormone estrogen. When estrogen binds it causes the
receptor to change shape to expose a surface where other proteins called coactivators can bind.
Once a coactivator is bound, the estrogen receptor is active and signals the cancer cell to grow,
divide, invade local tissues, and spread to new sites in the body.
Antiestrogen drugs competitively block the binding of estrogen to the receptor and cause the
receptor to take on a different shape that inhibits the binding of the coactivator. However, recent
studies identified mutations at specific sites in the gene that encodes estrogen receptor alpha in a
large subset of patients with breast cancers that have spread. These mutations make the receptor
resistant to antiestrogen drugs, and two mutations (called Y537S and D538G) account for
approximately 70% of cases. However, it was not clear how these mutations altered the activity of
estrogen receptor alpha at the molecular level.
Fanning, Mayne, Dharmarajan et al. now show these two most common mutations allow estrogen
receptor alpha to bind to the coactivator in the absence of hormone. This unfortunately also reduces
the effectiveness of one of the mostly widely administered antiestrogen therapies – a drug called
tamoxifen. However, Fanning, Mayne, Dharmarajan et al. also show that the newer and more potent
antiestrogens that are currently under examination in clinical trials should be highly effective at
treating the cancers with the mutated versions of estrogen receptor alpha.
Applying the knowledge gained from these new findings toward the development of new
antiestrogens could help reverse the impact of these common mutations. If successful, these new
drugs will provide life-saving treatments for many breast cancer patients.
DOI: 10.7554/eLife.12792.002
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function-2 (AF-2) cleft that governs the agonist or antagonist state of the receptor. In the agonist
conformation (e.g. estradiol (E2)-bound), H12 covers the ligand-binding pocket, docking between
Helices 3 (H3) and 11 (H11), thereby facilitating coactivator recruitment to the AF-2 cleft via canoni-
cal LXXLL coactivator sequence motifs. In contrast, in the antagonist state (e.g.SERM-bound), H12
occupies the AF-2 cleft using its own LXXML sequence, thereby blocking coactivator recruitment
and ERa action.
In this study, biophysical assays reveal the impact of the Y537S and D538G mutations on ERa
LBD ligand and co-regulator binding affinity. Additionally, x-ray crystal structures and atomistic
molecular dynamics (MD) simulations uncover altered conformations adopted by the mutant recep-
tors in the absence and presence of agonists and antagonists. Together, these findings present a
molecular explanation for how the Y537S and D538G mutations elevate the basal or constitutive
activity of ERa and confer resistance to the beneficial effects of the SERM, SERD, and AI therapies.
A comprehensive understanding of how these and other gain-of-function mutations alter the struc-
ture and function of ERa is crucial to development of more efficacious and potent inhibitors to tar-
get these mutant receptors in the clinic.
Results
Y537S and D538G promote constitutive coactivator binding to ERa
An established time-resolved Fo¨rster Resonance Energy Transfer (tr-FRET) assay that determines the
affinity of the steroid receptor coactivator 3 nuclear receptor domain (SRC3 NRD) for the ERs was
used to investigate differences among the WT, Y537S, and D538G (Tamrazi et al., 2005,
Jeyakumar et al., 2011). SRC3 was chosen because of its abundance in breast cancer cells and high
affinity for ERa (Liao et al., 2002). Table 1 summarizes all SRC3 coactivator binding affinities. SRC3
NRD bound to the E2-saturated WT ERa LBD with high affinity (Kd = 2.67 ± 0.5 nM) while no binding
was detected in the absence of E2 or in the presence of the SERM 4-hydroxytamoxifen (TOT; the
active metabolite of tamoxifen) (Figure 1). In contrast, the SRC3 NRD bound to Y537S and D538G
ERa in the absence of E2, with affinities of 13.6 ± 2.0 nM and 151 ± 20 nM, respectively, and the
binding curves reached approximately 60% of the maximum (Figure 1). When Y537S and D538G
were pre-saturated with E2, the SRC3 binding curves reached the same maximum as WT with E2,
with the coactivator binding affinity for the mutants being comparable or slightly higher than WT
(WT EC50 = 2.67 ± 0.5 nM; Y537S = 0.59 ± 0.1
nM; D538G = 3.65 ± 0.4 nM) (Figure 1). Neither
the WT nor the mutants bound coactivator when
pre-incubated with saturating concentrations
TOT (Figure 1).
To determine the potency of ligands to affect
coactivator binding to the ER, ligand was titrated
into a constant amount of SRC3 and ER and mea-
sured by tr-FRET. Addition of E2 resulted in
increased coactivator affinity to the Y537S (EC50
= 1.6 ± 1.2 nM) and D538G (EC50 = 2.2 ± 0.1 nM)
ERa LBD. Interestingly, the EC50 value was some-
what reduced for WT (EC50 = 13.8 ± 0.9 nM) (Fig-
ure 1—figure supplement 1). TOT abolished
basal Y537S and D538G SRC3 binding in the
absence of agonist. To mimic this reversal in WT,
which does not bind SRC3 NRD without ligand, a
low concentration of E2 was added to WT-ER to
recruit SRC3 NRD to about 50% of maximal (data
not shown). As expected, titration of TOT
reversed the binding of SRC3 NRD by the mutant
ER and E2-primed WT. The EC50 values for sup-
pressing SRC3 binding of the mutant (done in the
absence of agonist) were comparable to the Ki
Table 1. SRC3 NRD and ligand recruitment
affinities for the WT and mutant ERa
LBDs. LBD, ligand-binding domain.
SRC-3 NRD Kd (nM)
WT apo No Recruitment
Y537S apo 13.6 ± 2.0
D538G apo 151 ± 20
WT-E2 2.67 ± 0.5
Y537S-E2 0.59 ± 0.1
D538G-E2 3.65 ± 0.40
E2 EC50 (nM)
WT 13.8 ± 0.9
Y537S 1.6 ± 1.2
D538G 2.2 ± 0.1
TOT Ki (nM)
WT 1.82 ± 0.30
Y537S 6.7 ± 0.40
D538G 0.79 ± 0.04
DOI: 10.7554/eLife.12792.003
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Figure 1. Binding of the SRC3 coactivator to WT, Y537S, or D538G ERa LBD in the absence or presence of E2 or
TOT. LBD, ligand-binding domain.
DOI: 10.7554/eLife.12792.004
The following figure supplement is available for figure 1:
Figure supplement 1. Binding of the SRC3 coactivator to WT, Y537S, or D538G mutant ERa LBD with increasing
concentrations of E2 or TOT.
DOI: 10.7554/eLife.12792.005
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values for WT. The Ki of TOT was 1.82 ± 0.30 nM for WT, 6.7 ± 0.40 nM for Y537S, and 0.79 ± 0.04
nM for D538G.
The Y537S and D538G mutants bind ligands with reduced affinity
Our earlier work demonstrated that SERMs were less potent in inhibiting the transcriptional activity
of the ERa Y537S and D538G mutants compared to WT in breast cancer cells (Toy et al., 2013). The
binding affinities of E2 with the WT and mutant ERa LBDs were measured using radioligand bindin-
gligand-binding assays (Carlson et al., 1997). The affinity of E2 for WT-ER (Kd = 0.26 ± 0.13 nM) is
approximately five-fold greater than for the mutants, Y537S (Kd = 1.43 ± 0.55 nM) and D538G (Kd =
1.30 ± 0.63 nM) (Figure 2). Table 2 summarizes all ligand-binding affinities for the WT and mutant
ERa LBDs.
A competitive radioligand-binding assay with 3H-E2 as tracer was used to measure the relative
competitive binding affinities (RBAs) of TOT for WT and the mutant-ERs (Katzenellenbogen et al.,
1973; Carlson et al., 1997). The Ki of TOT binding to WT was 0.337 ± 0.018 nM, whereas it was
2.61 ± 0.60 nM and 3.42 ± 0.5 nM for the Y537S and D538G mutants, respectively. Comparing the
Ki values, it is notable that the affinity of TOT for the Y537S and D538G mutants is impaired approxi-
mately 8- and 10-fold relative to WT (Table 2). This reduced binding affinity is consistent with the
published lower inhibitory potency of TOT on the mutants in breast cancer cells (Toy et al., 2013).
Figure 3 shows representative radiometric competitive binding measurements.
Biophysical basis for aberrant coregulator recruitment by Y537S and
D538G ERa LBD mutants
Proteolytic susceptibility
An established trypsin digestion assay was used to determine whether the conformational dynamics
of the LBD H11-12 loop and H12 are altered as a result of the Y537S and D538G mutations
(Tamrazi et al., 2005). The measured half-life for H11-12 loop and H12 cleavage (t1/2) of the unli-
ganded (apo) WT ERa LBD was 2 min, indicating that this region is highly mobile (Figure 4A). In con-
trast, the H11-12 loop and H12 region displayed significantly reduced proteolysis for apo D538G,
with a t1/2 of 19 min. A further reduction was observed for the H11-12 loop and H12 for apo Y537S
with a t1/2 = 87 min. When incubated with saturating concentrations of E2, each of the LBDs dis-
played increased stability of the H11-12 loop and H12 with t1/2 = 5 min for the WT, 140 min for
Figure 2. Determination of Kd values of estradiol (E2) binding to wild type, Y537S, and D538G LBDs, by a direct
binding assay. All slopes had an r2 of 0.95 or better; shown is a representative experiment. For details, see
Methods. LBD, ligand-binding domain.
DOI: 10.7554/eLife.12792.006
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Y537S, and no detectible cleavage for D538G
(Figure 4A). This lack of proteolysis for the
D538G-E2 complex suggests that the H11-12
loop and H12 are stabilized and in a conforma-
tion that resists trypsin proteolysis. Importantly,
the trend of H11-12 loop and H12 mobility
observed for apo LBDs correlates with the rela-
tive coactivator binding affinities for apo WT and
mutant LBDs as the Y537S mutant is the least
dynamic and has the highest affinity for the
coregulator.
Hydrogen/deuterium exchange mass
spectrometry
Hydrogen/deuterium exchange mass spectrometry (HDX-MS) was used to further dissect the conse-
quences of Y537S and D538G ERa LBD mutations on the conformational mobility of the H11-12
loop and H12. Perturbation in time-dependent deuterium uptake profiles (measured as protection
to number of exchanged amide hydrogens with solvent deuterium between two states) is indicative
of conformational alterations due to rearrangement of amide hydrogen bonds (Horn et al., 2006).
Differential amide HDX experiments were performed to compare the conformational dynamics of
liganded and unliganded (apo) receptors. H11, the H11-12 loop, and H12 were all protected from
solvent exchange for WT, D538G, and Y537S ERa LBD in the presence of E2 as compared to apo
receptor (solvent exchange was lower for peptides containing these structural elements in the pres-
ence of ligand as compared to unliganded receptor), indicating the adoption of a more stable ago-
nist-bound conformation matching that observed in x-ray co-crystal structures (Figure 4B,C, and
Figure 4—figure supplements 1–3). For the unliganded states, the H12 of Y537S and D538G exhib-
ited increased solvent exchange (deprotection indicative of increased conformational dynamics)
compared to WT ERa, suggesting that the mutant receptors adopt an alternative H12 conformation
in the absence of E2. Figure 4B–C shows differential deuterium incorporation for the WT versus
mutant ERa LBD in the apo states focusing on the H11-12 loop and H12 regions. Figure 4—figure
supplements 4 and 5 show the complete differential HDX perturbation maps comparing the apo
Table 2. Ligand-binding affinities.
Kd (nM)
WT-E2 0.26 ± 0.13
Y537S-E2 1.43 ± 0.55
D537G-E2 1.30 ± 0.63
Ki (nM)
WT-TOT 0.337 ± 0.018
Y537S-TOT 2.61 ± 0.60
D538G-TOT 3.42 ± 0.50
DOI: 10.7554/eLife.12792.007
Figure 3. Relative binding affinity assay of wild type, Y537S, and D538G ligand-binding domains (LBDs), showing
the TOT competition curves. With all proteins, the E2 curve is set to 100% and is shown only once. For details, see
Methods.
DOI: 10.7554/eLife.12792.008
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Figure 4. Conformational stability of WT and mutant ERa LBD H11-12 loop and H12. (A) Proteolytic susceptibility of the WT, Y537S, and D538G ERa
LBD mutants in the apo, E2-bound, and TOT-bound states. (B–C) Deuterium uptake plot for the C-terminus of H11 along with the H11-12 loop and H12
for the apo WT vs Y537S ERa LBD (B), apo WT vs D538G ERa LBD (C). All HDX MS data represent an average of three replicates and are color coded
from red to blue with warm colors representing increased conformational dynamics (red being the highest D2O uptake) and cool colors representing
decreased conformational dynamics (blue being the lowest D2O uptake). All regions colored were determined to be statistically significant based on a
paired two-tailed Students t-test. A legend is provided at the bottom. Grey indicates no statistically significant change between the two apo
states. HDX, hydrogen/deuterium exchange; LBD, ligand-binding domain.
DOI: 10.7554/eLife.12792.009
The following figure supplements are available for figure 4:
Figure supplement 1. Complete differential amide HDX MS map of WT ERa LBD binding to E2.
DOI: 10.7554/eLife.12792.010
Figure supplement 2. Complete differential amide HDX MS map of Y537S ERa LBD mutant binding to E2.
DOI: 10.7554/eLife.12792.011
Figure supplement 3. Complete differential amide HDX MS map of D538G ERa LBD mutant binding to E2.
DOI: 10.7554/eLife.12792.012
Figure supplement 4. Complete differential HDX perturbation maps comparing the apo WT versus apo Y537S ERa LBD.
DOI: 10.7554/eLife.12792.013
Figure supplement 5. Complete differential HDX perturbation maps comparing the apo WT versus apo D538G ERa LBD.
DOI: 10.7554/eLife.12792.014
Figure supplement 6. Complete differential HDX perturbation map of WT ERa LBD with SRC3-NRD.
DOI: 10.7554/eLife.12792.015
Figure supplement 7. Complete differential HDX perturbation map of Y537S ERa LBD with SRC3-NRD.
DOI: 10.7554/eLife.12792.016
Figure supplement 8. Complete differential HDX perturbation map of D538G ERa LBD with SRC3-NRD.
DOI: 10.7554/eLife.12792.017
Figure supplement 9. Complete differential HDX perturbation map of WT ERa LBD with E2 and SRC3-NRD.
DOI: 10.7554/eLife.12792.018
Figure supplement 10. Complete differential HDX perturbation map of Y537S ERa LBD with E2 and SRC3-NRD.
DOI: 10.7554/eLife.12792.019
Figure supplement 11. Complete differential HDX perturbation map of D538G ERa LBD with E2 and SRC3-NRD.
DOI: 10.7554/eLife.12792.020
Figure supplement 12. apo Y537S x-ray crystal structure (Yellow) (PDB: 2B23) superimposed with WT-E2 complex structure (White) (PDB: 1GWR).
DOI: 10.7554/eLife.12792.021
Fanning et al. eLife 2016;5:e12792. DOI: 10.7554/eLife.12792 7 of 25
Research article Biophysics and structural biology Human biology and medicine
WT versus apo Y537S and D538G ERa LBD, respectively. Interestingly, residues close in space to or
within the AF-2 cleft (positions 310–325, 344–349, 370–380, and 405–410) of the apo Y537S also
showed statistically significant increase in solvent exchange compared to apo WT. Similar deprotec-
tion was observed in residues 310–325 of the apo D538G. Together, the HDX data suggests that the
Y537S and D538G mutants enables H12 to sample a suite of conformations that expose the AF-2
cleft at a greater frequency thereby facilitating coregulator recruitment in the absence of hormone.
Furthermore, these data suggest that the Y537S mutant possesses a higher affinity for SRC3 as com-
pared to D538G as it samples more frequently AF-2-cleft conformers that facilitate coregulator bind-
ing, in agreement with our in vitroSRC3 NRD-binding experiments.
In order to test our hypothesis that the increased deuterium uptake in the H12 region of the
mutants was due to a rearrangement of amide hydrogen bonds that could facilitate coactivator
recruitment, we performed differential HDX analysis for the WT, Y537S, and D538G ERa LBDs in the
presence of SRC3 NRD, in the presence and absence of E2. Few statistically significant differences in
solvent exchange were observed in the C-terminus of LBD when the WT ERa LBD was incubated
with saturating concentrations of SRC3 NRD, with the exception of H11 (Figure 4—figure supple-
ment 6). In contrast, the H11-12 loop showed statistically significant protection from exchange in
the Y537S-SRC3 NRD complex, indicating that the region in the Y537S mutant was further stabilized
by the inclusion of coregulator (Figure 4—figure supplement 7). These results suggest that H12 in
the apo mutant receptor is in a more favorable conformation promoting co-activator binding when
compared to apo WT. The magnitude of protection from solvent exchange observed in the AF-2
cleft in Y537S with SRC3 NRD was further increased upon addition of E2 indicating a more stable
Y537S-SRC3-E2 complex (Figure 4—figure supplement 10). In contrast to Y537S, the H11-12 loop
and H12 in the D538G mutant did not show a statistically significant difference in deuterium incorpo-
ration in the presence of SRC3 NRD alone, but did show increased protection from solvent exchange
in these regions in the presence of E2 (Figure 4—figure supplements 8 and 10). This finding could
be attributed to the low intrinsic SRC3 NRD-binding affinity of apo D538G as compared to Y537S
(Table 1). Together, these data, along with the SRC3 NRD recruitment and trypsin susceptibility,
suggest that the increased solvent exchange in H12 and AF-2 cleft residues for the apo Y537S is due
to an altered conformation of H12 that promotes coactivator recruitment. This observation is appar-
ent in the x-ray crystal structure of the apo Y537S. When compared to the WT-E2 complex (PDB:
1GWR), the serine at residue 537 in the apo Y537S (PDB: 2B23) replaces the phenolic side chain of
WT Y537, exposing a solvent channel between the H11-12 loop and H3. Further, H12 is slightly dis-
placed away from the ligand-binding pocket toward solvent (Figure 4—figure supplement 12). It is
important to note that the HDX MS studies provide novel insight into the conformational mobility of
the WT H12, in that this helix does not reach maximum structural stability until both hormone and
coregulator are bound.
Structural basis for H12 mutant hormone-independent activity
X-ray crystallographic analysis of the D538G agonist states
High resolution x-ray crystal structures of the apo and agonist-bound states of the Y537S, obtained
earlier, revealed near identical H12 conformations, in which S537 formed a hydrogen bond with
D351 to adopt a stable agonist state in the absence of hormone (Nettles et al., 2008). In this study,
we obtained x-ray crystal structures for the D538G mutant bound to E2, without added ligand (apo),
and bound to a SERM (4-hydroxytamoxifen).
D538G mutation induces pronounced conformational changes in the
agonist-binding mode
The D538G-E2 complex structure was solved to 1.90 A˚ resolution by molecular replacement, with
one dimer in the asymmetric unit (ASU). All crystallographic statistics are reported in Table 3. Over-
all, the structure presents a canonical ERa LBD-agonist binding state where H12 covers the ligand-
binding pocket situated between H3 and H11, and the GRIP peptide occupies the AF-2 cleft. The E2
ligand, GRIP peptide, and H12 (until residue L549) are well resolved in the map (Figure 5—figure
supplement 1). No differences are observed in the residues comprising the ligand-binding pocket
between the D538G-E2 and WT-E2 structures (Gangloff et al., 2001; Eiler et al., 2001;
Phillips et al., 2011).
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Pronounced conformational changes are observed in the loop connecting H11 and H12 (H11-12
loop, residues 531–537) in both monomers in the ASU for the D538G-E2 structure compared to the
WT-E2 structure, although no appreciable changes are observed in most of H12. The H11-12 loop is
displaced away from H3 and toward H11, accompanied by conformational changes in Y537 (Fig-
ure 5). In the WT-E2 structure, Y537 forms a hydrogen bond with N348 on H3, packing the H11-12
loop into the interior of the protein. In the D538G-E2 structure, however, the Y537 loses its hydro-
gen bond with N348, and its phenolic side chain is pointed toward bulk solvent. The space previ-
ously occupied by Y537 in WT is replaced by a well ordered water molecule in the mutant (observed
in both monomers), which hydrogen bonds with the backbone amide of Y537 in between H3 and
H12 (Figure 5—figure supplement 2). While the side-chain orientations are identical for residues
531–536 between both monomers in the ASU, the side chain of Y537 appears to adopt two different
conformations, both facing solvent, while the main chain orientation of Y537 is identical in the two
monomers. It should be noted that the phenolic oxygen of Y537 maintains the same hydrogen bond
to N348 in every WT ERa LBD-agonist structure available in the PDB. Thus, this rotation of Y537 is
unique to the D538G-E2 structure, and it brings the j and y angles of residues 537 and 538 out of
the a-helix region and into the allowed, more sheet-like region around -120˚ and 60˚ (defined by j/
y angle regions in the Ramachandran plot) (Ramachandran et al., 1963). In the resulting conforma-
tion, the a-helix of H12 begins at position 539 for the D538G-E2 structure rather than at 537 for the
WT-agonist structures.
Table 3. Crystallographic data collection and refinement statistics.
ERa LBD D538G Apo ERa LBD D538G-E2 ERa LBD D538G-4OHT
Data collection
Space group P21 P21 P212121
a, b, c (A˚) 56.14, 82.66, 59.11 56.08, 84.18, 58.37 104.65, 104.65, 191.38
a, b, g (˚) 90.00, 111.05, 90.00 90.00, 108.83, 90.00 90.00, 90.00, 90.00
Resolution range 55.17-2.24 A˚ 55.25-1.90 50.00-3.07
Number of reflections
(all/unique) 91,607/24,107 169,519/40,361 60,232/9,874
I/s (highest resolution) 2.37 2.36 1.70
Rmerge 11.4 7.3 11.4
Completeness (%) 98.9 99.3 96.7
Redundancy 3.8 4.2 6.1
Refinement
Rwork/Rfree 19.8/24.9 17.9/21.4 21.6/28.3
No. Residues/chain
ERa LBD D538G 241 242 216
GRIP peptide 6 6 0
Water 16 44 2
Ligand 0 1 1
RMSD
Bond lengths (A˚) 0.015 0.0170 0.0128
Bond angles (˚) 1.76 1.5441 1.5356
Chiral volume 0.1117 0.1267 0.1036
Ramachandran plot statistics
Preferred number (%) 428 (96.40%) 443 (98.88%) 1,563 (95.42%)
Additional allowed (%) 3.60 (3.6%) 5 (1.12% ) 75 (4.58%)
Outliers (%) 0 0 0
DOI: 10.7554/eLife.12792.022
Fanning et al. eLife 2016;5:e12792. DOI: 10.7554/eLife.12792 9 of 25
Research article Biophysics and structural biology Human biology and medicine
Few differences are observed between the unliganded and E2-bound D538G (Ca r.m.s.d. =
0.327 A˚). The greatest conformational discrepancy between the two structures lies at Y537, which, in
the unliganded structure, adopts a more WT-E2 like conformation by orienting toward H3 in chain
A, thus returning the j and y angles of residues 537 and 538 into the a-helical region. Y537 of chain
B, however, matches the solvent-exposed orientation of the D538G-E2 structure whereby the j and
y angles for 537 and 538 are outside of the a-helical region. Based on this conformational asymme-
try between the two monomers in apo-D538G ERa, Y537 can switch between the buried state
observed in the WT-agonist structures and the solvent-exposed orientation of the D538G-E2 struc-
ture (Figure 5—figure supplement 2A and B). Thus, apo D538G has lost some—but not all—of the
conformational attributes of the E2-bound mutant, which is consistent with its modest level of consti-
tutive activity. Together, these structural features agree with our biophysical data showing that
D538G can adopt an agonist state in the absence of hormone that recruits coregulator with a mod-
est affinity.
It is of interest that the electron density map of apo D538G revealed some density in the ligand-
binding pocket representing a non-specific small molecule likely acquired during the expression of
the protein, which remained during crystallization (Figure 5—figure supplement 3). A similar elec-
tron density was observed in the published apo Y537S (Nettles et al., 2008). The unidentified ligand
is not of sufficient size to be a hormone nor is it near enough to H11 and H12 to interact with them.
Figure 5. Stabilized D538G agonist state. Superposition stereo-view image of the residues comprising the H11-12
loop (531–537) of monomer A of the D538G-E2 (cyan) overlaid with monomer A of the WT-E2 structure (PDB:
1GWR). E2 is represented as green sticks. Coactivator peptide is shown as light-yellow ribbon.
DOI: 10.7554/eLife.12792.023
The following figure supplements are available for figure 5:
Figure supplement 1. Simulated annealing composite omit maps for the E2 (A) and TOT (B)-bound D538G ERa
LBD crystal structures contoured to 1.5s.
DOI: 10.7554/eLife.12792.024
Figure supplement 2. Y537 orientations for D538G and WT LBD.
DOI: 10.7554/eLife.12792.025
Figure supplement 3. Density of an unidentified small molecule in the ligand-binding site of the apo D538G x-ray
crystal structure.
DOI: 10.7554/eLife.12792.026
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We believe that the unidentified small molecule in the ligand-binding site is an artifact of protein
expression in bacteria, as reported earlier for the Y537S structure, and does not influence H11 and
H12 nor the loop connecting them (Nettles et al., 2008).
The dynamics of D538G-mediated alterations of the H11-12 loop
The previously published apo Y537S structure showed that S537 forms a hydrogen bond with D351
to adopt the agonist state in the absence of hormone thereby providing a clear conformational
explanation for its constitutive activity (Nettles et al., 2008). In contrast, the apo D538G structure
shows that this mutant may use a subtler mechanism to adopt the agonist conformation in the
absence of hormone. In order to gain a better understanding of how the D538G mutation stabilizes
the ERa LBD agonist conformation, MD simulations were performed on this mutant in the absence
of ligand, and for WT ER (Figure 6A) in both the presence and absence of ligand. As was noted ear-
lier, it has not been possible to obtain crystal structures of apo WT ER. Thus, to gain insights into
the apo WT ERa LBD, MD simulations were performed by removing E2 from the ER complex prior
to the dynamics run.
MD simulations of the WT and the D538G mutant showed an increased flexibility of the H11-12
loop as a result of the D538G mutation, inducing the Y537 side chain to rotate toward the bulk sol-
vent (Figure 6B). This rotation shifts the backbone conformations of residues 535–537 (Figure 6E) to
Figure 6. Visualization of H11-12 loop dynamics. (A) H11-12 loop of WT ERa LBD-E2 complex. (B) Superimposing the position of the phenolic oxygen
of Y537 at 0.1-ns intervals for apo WT (red), WT-E2 (blue), and apo D538G mutant (green). (C) Mapping the mass density isosurface (0.75, i.e., 25th
percentile) of the hydrophobic side chains in the linker region (V533, V534, P535, and L536). (D) Side-chain packing of the apo D538G structure
compared to WT-E2. (E) Ramachandran analysis of residues 534–538 for the apo WT, WT-E2, and apo D538G MD simulations. (F) Time series of the
solvent accessible surface area (SASA) for hydrophobic loop residues (533–536). LBD, ligand binding domain.
DOI: 10.7554/eLife.12792.027
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occupy regions of the Ramachandran plot that are similar to WT-E2 and distinct from apo-WT. These
mutation-induced changes allow the H11-12 loop to adopt conformations similar to WT-E2, despite
the absence of ligand. Computing the density maps for the side-chain atoms of hydrophobic resi-
dues V533, V534, P535, and L536 further confirmed this altered state in which the resulting back-
bone conformation also permits new side-chain positions (Figure 6C,D). Analysis of the averaged
atomic density for residues 533–536 in the WT simulations reveals that the removal of the ligand
(WT-E2 vs. apo WT, Figure 6C) results in more exposed positions for the hydrophobic residues in
the loop region, thus destabilizing the H11-12 loop, while the D538G mutation allows the receptor
to maintain side-chain positions buried more deeply into the protein surface (WT-E2 vs. apo D538G,
Figure 6D). Further, reduced fluctuations were exhibited in the WT-E2 and apo-D538G MD simula-
tions, as observed from larger volumes for the given isosurface, thus indicating that the residues
pack more favorably. The optimized packing of the hydrophobic loop residues was additionally
quantified by the decreased solvent exposure for the WT-E2 and apo D538G conformations com-
pared to apo WT over the course of the entire simulation (Figure 6F). All of the changes that result
from replacing D538 with glycine are consistent with increased stability of the H11-12 loop in the
mutant, which likely contributes to its constitutive activity.
Structural and biophysical Basis for reduced SERM potency
Trypsin susceptibility of the H12 mutants with TOT
Trypsin susceptibility was used to determine whether the antagonist state dynamics of the H11-12
loop and H12 were altered as a result of Y537S or D538G mutation. Interestingly, these regions
showed decreased dynamics (i.e. increased stability) for the Y537S and D538G mutants, which dis-
played t1/2 = 60 and 62 min, respectively, whereas the t1/2 for the WT was 18 min (Figure 4A). These
half-lives were higher than apo proteins alone suggesting that TOT binds and increases the overall
stability of the protein (Figure 4A), although to a lesser extent than does E2.
HDX MS of the WT and mutants in complex with TOT
HDX MS was employed to probe the sequence-specific conformational mobility of the Y537S and
D538G antagonist states compared to the WT. Comparison of HDX profiles for TOT-bound WT and
mutants revealed that the mutant proteins adopt alternate conformations in H11/12 regions relative
to the WT complex (Figure 7C–E). Figure 7—figure supplements 1–3 show deuterium uptake plots
for the WT and mutant ERa LBDs in complex with TOT for the full protein sequence. Additionally,
Figure 7—figure supplements 4–6 show side-by-side comparisons for the WT, Y537S, and D538G
ERa LBD in complex with ligand and/or SRC3 NRD versus their individual apo states.
Structure of the D538G-TOT complex
To explore the structural basis for reduced SERM potency and efficacy, the D538G mutant ERa LBD
was co-crystallized with TOT. We were unable to obtain diffraction-quality crystals for Y537S in com-
plex with any SERM. However, the D538G-TOT structure was solved to 3.06 A˚ with four dimers in
the ASU by molecular replacement. The TOT ligand and H12 are both well resolved in every mono-
mer (Figure 5—figure supplement 1B). Significant conformational differences are observed
between WT-TOT (PDB: 3ERT) and D538G-TOT structures, both in H12 and the H11-12 loop
regions. We believe that these differences help account for the reduced potency and efficacy of
TOT toward the D538G mutant ERa in breast cancer reporter gene assays.
As with the WT-TOT structure, H12 of the D538G-TOT structure lies in the AF-2 cleft; the confor-
mation of H12 in the mutant structure, however, is altered compared to the WT (Figure 7A). In
D538G-TOT, L536 is oriented toward solvent rather than docking into the well-defined leucine-bind-
ing pocket found in the WT-TOT structure, and P535 occupies the space previously occupied by the
L536 of the WT (Figure 7A). The largest conformational change occurs in the H11-12 loop (residues
527–537). Instead of extruding toward solvent, the loop is packed toward the interior of the protein
by 9.6 A˚ compared to the WT (V534 alphacarbon to alpha carbon) (Figure 7A). This conformational
change likely explains why trypsin displayed a reduced ability to cleave at this region. Additionally,
the tertiary amine at the terminus of the TOT ligand is observed in several conformations in the com-
plex with D538G ER rather than the single conformation present in the WT-TOT structure. Together,
these observations suggest that the flexibility of a glycine at position 538 reduces the ability of an
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antagonist to influence the H11-12 loop and H12. However, care must be taken when interpreting
differences within this loop between the WT and the D538G mutant crystal structures. A crystal con-
tact is formed in the WT-TOT structure between the backbone amide of K531 with the backbone
carbonyl oxygen of K492 in a symmetry mate. Together, these data reveal that the D538G mutant
adopts an altered antagonist conformation that resists antagonism relative to the WT-TOT complex.
Figure 7. Alterations to the D538G and Y537S antagonist conformational states. (A) Superposition of monomer A for the 538G-TOT structure with the
WT (3ERT). TOT and residues 530–550 of the WT (blue) (PDB: 3ERT), TOT of D538G (green), residues 531–550 (red). (B) Predicted conformational
alterations in H12 in the Y537S-TOT structure (red) compared to the WT-TOT (blue). (C) HDX-MS of the WT-TOT complex for H11 through H12 regions.
(D) HDX-MS of Y537S-TOT complex for H11 through H12 regions. (E) HDX-MS of the D538G-TOT complex for H11 through H12 regions. HDX data is
color coded as in 2C. See methods for more details on coloring scheme. HDX-MS, hydrogen/deuterium exchange mass spectrometry; LBD, ligand
binding domain.
DOI: 10.7554/eLife.12792.028
The following figure supplements are available for figure 7:
Figure supplement 1. Complete differential amide HDX-MS map of WT ERa LBD binding to TOT.
DOI: 10.7554/eLife.12792.029
Figure supplement 2. Complete differential amide HDX-MS map of Y537S ERa LBD mutant binding to TOT.
DOI: 10.7554/eLife.12792.030
Figure supplement 3. Complete differential amide HDX-MS map of D538G ERa LBD mutant binding to TOT.
DOI: 10.7554/eLife.12792.031
Figure supplement 4. Experiment comparison view comparing the differential HDX behavior of apo WT ERa LBD in the presence of various ligands or
coactivator.
DOI: 10.7554/eLife.12792.032
Figure supplement 5. Experiment comparison view comparing the differential HDX behavior of apo Y537S ERa LBD in the presence of various ligands
or coactivator.
DOI: 10.7554/eLife.12792.033
Figure supplement 6. Experiment comparison view comparing the differential HDX behavior of apo D538G ERa LBD in the presence of various ligands
or coactivator.
DOI: 10.7554/eLife.12792.034
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Modeled structure of the Y537S-TOT complex
MD simulation was used to model Y537S with TOT because we were unable to obtain diffraction
quality crystals for the complex. During the simulation, H12 of Y537S was found to lie within the AF-
2 cleft in a perturbed conformation compared to the WT-TOT crystal structure, similar to that seen
in the D538G-TOT crystal structure. Specifically, L536 no longer packs well with the leucine binding
site on H3 but reorients to face the solvent, and the rest of the motif is also pushed outward and
even shifted toward the C-terminus along the axial direction of H12 by half a turn (Figure 7B). These
findings suggest that Y537S stabilizes H12 inside the AF-2 through the formation of a newly formed
hydrogen bond (Figure 7B) that is predicted to form between S537 and E380. Like the D538G-TOT
complex, our data for the Y537S-TOT complex show that these conformational changes serve to
reduce the inhibitory potency of the SERM relative to the WT ERa LBD.
Discussion
Acquired resistance to endocrine therapies represents a substantial barrier toward obtaining pro-
longed remission of ER-dependent metastatic breast cancers for a significant population of patients.
While somatic mutations in the androgen receptor are a known mechanism of acquired hormone
therapy resistance in prostate cancer, somatic mutations in ESR1 have only recently been identified
as an important mechanism of acquired endocrine therapy resistance in breast cancer. Subsequent
studies have established Y537S and D538G as the two most common point mutations conferring
hormone-independent activation and reduced SERM/SERD/AI inhibitory potency and likely efficacy
(Robinson et al., 2013; Toy et al., 2013; Jeselsohn et al., 2014). The clinical importance of these
ESR1 mutations highlights the importance of understanding the mechanisms by which they influence
ERa structure and function.
Here, biochemical and biophysical techniques combined with x–ray crystal structures, and MD
simulations provide a molecular explanation for how the Y537S and D538G point mutations in the
ERa LBD alter the structure and function of the receptor. Coactivator binding assays show that these
mutant LBDs recruit the SRC3 coactivator in the absence of hormone, while the unliganded WT LBD
does not. Importantly, apo Y537S binds SRC3 NRD with a significantly increased affinity compared
to D538G. This differential coactivator binding affinity likely accounts for the significantly increased
constitutive transcriptional activity of Y537S versus D538G in breast cancer cell line reporter gene
assays (Toy et al., 2013). Figure 8 shows a model for aberrant ERa activity as a result of Y537S and
D538G mutations in the recurrent anti-estrogen-resistant breast cancer cell. Ligand-binding assays
demonstrate that both mutants possess a slightly reduced affinity for E2 and a significantly reduced
affinity for TOT. Collectively, these data suggest that the combination of a recruitment of coactivator
in the absence of hormone and a reduced TOT-binding affinity underlie the hormone therapy resis-
tance conferred by these H12 ERa mutations.
Comprehensive biophysical and structural investigations by proteolytic susceptibility assays, HDX-
MS, x-ray crystallography, and MD simulations reveal how the Y537S and D538G mutations affect
ERa in the apo, agonist, and antagonist-bound states, thereby providing a detailed structural expla-
nation for the hormone-resistance conferred to the ERa. The Y537S and D538G mutations are
located at or near H12, a key molecular switch governing the ligand-regulated actions of ERa via
AF-2. Previously published apo and agonist-bound Y537S structures showed that S537 promotes the
agonist conformation in the absence of ligand by forming a hydrogen bond to D351 (Nettles et al.,
2008), in the process facilitating a tighter packing of the H11-12 loop against the LBD. Similarly, our
analysis of the agonist-bound and apo D538G structures show that this mutation relaxes the helical
character at the start of H12, thereby also relaxing the H11-12 loop and improving the packing of its
hydrophobic side chains. Importantly, our data also show that binding of coregulator (SRC3) further
stabilizes H12 in the agonist conformation. While the Y537S and D538G mutants may work through
different mechanisms, both stabilize the agonist state in the absence of hormone. The D538G muta-
tion, however, appears to be less stabilizing, as reflected by the lower constitutive activity of D538G
ERa in both biochemical and cell-based assays (Toy et al., 2013).
Examination of the molecular basis for reduced SERM potency and efficacy for mutant ERa LBDs
reveals that this likely evolves from structural changes to the H11-12 loop, resulting in a decreased
binding affinity of antagonist ligands and an altered, stabilized, antagonist conformation of H12 in
the AF-2 cleft. Our biophysical studies indicate that the H11-12 loop and H12 are both altered when
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TOT is bound in the Y537S and D538G mutants compared to the WT. Further, when compared to
the WT-TOT structure, the D538G-TOT structure shows an altered conformation of the H11-12 loop
and H12 occupancy of the AF-2 cleft, and multiple conformations of the TOT ligand (indicative of
reduced influence on the H11-12 loop). Additionally, MD simulation of the Y537S-TOT complex
shows that S537 might form a hydrogen bond with E380 that alters the antagonist conformation.
Therefore, the reduced inhibitory potency of TOT stems from its reduced affinity for the Y537S and
D538G mutants along with conformational changes to the antagonist state once it occupies the
ligand-binding site.
Taken together, these results suggest that the constitutive activity conferred by the Y537S and
D538G mutations stems from the intrinsic ability of the mutant receptors to adopt a stable agonist
conformation in the absence of hormone, thereby leading to enhanced recruitment of SRC3 coacti-
vators and increased ERa transcriptional activity. This pre-organized agonist state contributes to a
decreased affinity for hormone and especially for SERMs because the stabilized H12 agonist confor-
mation restricts ligand access to the hormone-binding pocket. In addition to reduced ligand affinity,
SERM action is further reduced by an altered antagonist state of H12. Thus, recruitment of coactiva-
tors in the breast cancer cell is not inhibited as efficiently for the Y537S and D538G mutants as for
WT ERa.
One caveat to the approach described in this study is that ERa is a multi-domain protein and only
the LBD was used for structural studies. To gain deeper insight into how these mutations affect full
length ERa, further studies on intact multi-domain protein will be necessary. In addition, the effect
of these mutations on the other aspects of ERa action including other hormone/SERM/SERD binding
affinities, homodimer formation, DNA-binding, and stability (in vitro and in vivo) and whether these
mutant receptors display a differential preference for a spectrum of coactivators must be
investigated.
Our findings suggest that SERMs and SERDs that are designed to specifically increase the dynam-
ics of H12 might lead to drugs with increased potency. In this regard, our data show that the H11-12
loop plays an important and previously unrecognized role in regulating the behavior of H12, an
essential molecular switch that is allosterically controlled by ligand, which determines the differential
ability of the ERa AF-2 to recruit coactivators and corepressors. Therefore, antagonists with
Figure 8. Model of Aberrent ERa Mutant Activity. Upon hormone binding (E2), WT ERa sheds heat-shock/
chaperone proteins (HSP), forms head-to-head homodimers, and recruits coactivator (CoA) to become active. By
contrast, Y537S or D538G ERa mutants adopt the active conformation in the absence of hormone to recruit CoA
and achieve constitutive activity. Additionally, E2 binding may further increase mutant activity.
DOI: 10.7554/eLife.12792.035
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improved inhibitory potency will increase the dynamic character of mutant H12, an already appreci-
ated aspect of SERD action (Pike et al., 2001). Additionally, our work provides a biophysical hypoth-
esis for why fulvestrant (a SERD, known to disorder H12) was the only molecule which could
completely ablate the transcriptional activity of the Y537S and D538G mutants in breast cancer cells
while TOT (a SERM) could not (Toy et al., 2013). Therefore, newly developed mixed SERM/SERDs
and SERDs with improved pharmacokinetics and oral bioavailability over fulvestrant, such as AZ9496,
bazedoxifene, GDC910, and RAD1901, should be particularly effective against cancers expressing
the Y537S and D538G ESR1 mutants (De Savi et al., 2015; Garner et al., 2015; Lai et al., 2015;
Wardell et al., 2013). These compounds may prove invaluable for treating endocrine therapy-resis-
tant ER+ breast cancers and also preventing or delaying the appearance of these somatic mutations
in early-stage patients.
Materials and methods
Time resolved-FRET assays
Protein preparation for TR-FRET
Site-directed mutagenesis was used to generate the Y537S and D538G mutations in the LBD of the
human estrogen receptor a (ERa amino acids 304–554). The WT and mutant ERa and the nuclear
receptor domain (NRD) of human SRC3 encompassing three NR boxes (amino acids 627–829) were
expressed in E. coli, using methods reported previously (Jeyakumar et al., 2011; Carlson et al.,
1997). ER LBDs of wild type, Y537S, and D538G were prepared as 6His fusion proteins, with a sin-
gle reactive cysteine at C417. While bound to the Ni-NTA-agarose resin (Qiagen Inc., Santa Clarita,
CA), the ERs were labeled with MAL-dPEG4-biotin (Quanta BioDesign, Powell, OH), site-specifically
at C417. The SRC3-NRD construct has 4 cysteines and was labeled non-specifically, also while on the
resin, with 5-iodoacetamido fluorescein (Molecular Probes, Invitrogen, Eugene, OR). It was previ-
ously determined that an average of 1.8–2 fluorescein molecules are attached to the SRC3 NRD
(Kim et al., 2005).
SRC titration
SRC3 was titrated into a fixed amount of ERa-LBD-biotin mixed with SaTb (streptavidin-terbium,
Invitrogen, Grand Island, NY), on 96-well black microplates (Molecular Devices, Sunnyvale, CA) fol-
lowing previously determined methods (Jeyakumar et al., 2011). The time-resolved Fo¨rster reso-
nance energy transfer (tr-FRET) measurements were performed with a Victor X5 plate reader (Perkin
Elmer, Shelton, CT) with an excitation filter at 340/10 nm and emission filters for terbium and fluores-
cein at 495/20 and 520/25 nm, respectively, with a 100 ms delay. Diffusion-enhanced FRET was
determined by a parallel incubation without biotinylated ER-LBD and subtracted as a background
signal. The final concentrations of reagents were: 1 nM ERa-417, 0.25 nM streptavidin-terbium, 1
mM ligand, SRC3-F1 coactivator titrated from 3.210-7 to 3.210–12M. The data, representing 2–3
replicate experiments, each with duplicate points, were analyzed using GraphPad Prism 4 and are
expressed as the EC50 in nM.
Ligand titration
Ligands were titrated into a constant amount of ER-LBD-biotin, SaTb, SRC3-F1. The final concentra-
tions were 1 nM ER-LBD, 0.25 nM SaTb, 100 nM SRC3-fluorescein, and increasing ligand concentra-
tions from 110-12to 110-6 M. Diffusion-enhanced FRET was determined by a parallel incubation
without biotinylated ER-LBD and subtracted as a background signal. The tr-FRET was measured with
a Victor X5 plate reader as outlined above. The data, representing 2–3 replicate experiments, each
with duplicate points, was analyzed using GraphPad Prism 4, and are expressed as the EC50 in nM.
Ligand-binding assays
Relative binding affinities (RBA) were determined by a competitive radiometric binding assay with 2
nM [3H]-E2 as tracer, as a modification of methods previously described (Katzenellenbogen et al,
1973: Carlson et al., 1997). Incubations were at 0˚C for 18–24 hr. Hydroxyapatite was used to
absorb the receptor-ligand complex, and unbound ligand was washed away. The determination of
RBA values is reproducible in separate experiments with a CV of 0.3. The IC50 values for inhibition of
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[3H]-E2 were converted to Ki values using the Cheng-Prusoff equation (Ki = IC50/(1 + conc. tracer/Kd
tracer))(Cheng and Prusoff 1973); this was necessary because the affinity of the [3H]-E2 tracer is dif-
ferent for WT and mutant ERs. The Kd of [
3H]-E2 for the ERs was determined in a saturation-binding
assay, as 0.26 ± 0.13 nM for the WT, 1.43 ± 0.55 nM for Y537S, and 1.30 ± 0.63 nM for D538G (Fig-
ure 2). For the saturation ligand binding (Scatchard analysis), protein was diluted to 0.8 nM, in Tris-
glycerol buffer (50 mM Tris pH 8.0, 10% glycerol, with 0.01 M 2-mercaptoethanol and 0.3 mg/mL
ovalbumin added) and incubated with various concentrations of [3H]-E2 (Perkin-Elmer, Waltham,
MA) in the absence or presence of a 100-fold excess of unlabeled ligand for 3–4 hr, at 0˚C. Aliquots
of the incubation solution were used to determine the total [3H]-E2 in the sample. The incubation
solutions were then assayed by adsorption onto HAP (hydroxyapatite, BioRad, Hercules, CA) and
the free estradiol was washed away. Data were processed by GraphPad Prism 4 according to the
method of Scatchard (Scatchard, 1949; Hurth et al., 2004).
Trypsin proteolysis
Protein was prepared and labeled as described above for the trFRET assays. It was incubated in t/g
buffer with or without 1 mM of ligand, at room temperature for 1 hr. Then, 1 mg trypsin per unit of
protein was added for 10, 30, 60, and 300 min at room temperature according to previously estab-
lished methods (Tamrazi et al., 2005). FRET signal was measured using a Victor X5 plate reader as
outlined above. The data, representing 2–3 replicate experiments, were analyzed using GraphPad
Prism 4, and are expressed as half-lives (t1/2).
Hydrogen deuterium exchange
Differential hydrogen/deuterium exchange (HDX) MS
Solution-phase amide HDX experiments were carried out using a fully automated system as
described previously with slight modifications.(Chalmers et al., 2006) Prior to HDX, 10 mM of 6-
HIS-ERa-LBD (WT or mutants) were incubated with 100 mM of individual ligands for 1 hr on ice for
complex formation. Differential HDX experiments with ligands were initiated by mixing either 5 ml of
the ERa LBD alone (apo) or the complex (1:10 molar mixture of ERa and ligands) with 20 ml of D2O-
containing HDX buffer (20 mM Tris 8.0, 150 mM NaCl, and 3 mM DTT). For the differential HDX
experiments with SRC3 NRD, 10 mM of WT or mutant ERa LBDs were mixed with 25 mM of SRC3
NRD for 2 hr on ice for complex formation and then subjected to HDX as described above. For the
apo ERa comparisons, 10 mM of WT or mutant ERa LBDs were run in a similar differential format
comparing either Y537S or D538G directly with the WT. Twenty-five microliter aliquots were drawn
after 0 s, 10 s, 30 s, 60 s, 900 s or 3,600 s of on-exchange at 4˚C and the protein was denatured by
the addition of 25 ml of a quench solution (1% v/v TFA in 5 M urea and 50 mM TCEP). Samples were
then passed through an immobilized pepsin column at 50 ml min-1 (0.1% v/v TFA, 15˚C). and the
resulting peptides were trapped on a C8 trap column (Hypersil Gold, ThermoFisher, Grand Island,
NY). The bound peptides were then gradient-eluted (5–50% CH3CN w/v and 0.3% w/v formic acid)
across a 1 mm  50 mm C18 HPLC column (Hypersil Gold, ThermoFisher, Grand Island, NY) for
8 min at 4˚C. The eluted peptides were then subjected to electrospray ionization directly coupled to
a high-resolution Orbitrap mass spectrometer (LTQ Orbitrap XL with ETD, Thermo Fisher).
Peptide identification and HDX data processing
MS/MS experiments were performed with a LTQ linear ion trap mass spectrometer (LTQ Orbitrap
XL with ETD, Thermo Fisher) over a 70-min gradient. Product ion spectra were acquired in a data-
dependent mode and the five most abundant ions were selected for the product ion analysis. The
MS/MS *.raw data files were converted to *.mgf files and then submitted to Mascot (Matrix Science,
London, UK) for peptide identification. Peptides included in the peptide set used for HDX detection
had a MASCOT score of 20 or greater. The MS/MS MASCOT search was also performed against a
decoy (reverse) sequence, and false positives were ruled out. The MS/MS spectra of all the peptide
ions from the MASCOT search were further manually inspected, and only the unique charged ions
with the highest MASCOT score were used in estimating the sequence coverage. The intensity-
weighted average m/z value (centroid) of each peptide isotopic envelope was calculated with the lat-
est version of our in-house software, HDX Workbench (Pascal et al., 2012). HDX data are presented
as an average of three independent triplicates. Deuterium uptake for each peptide is calculated as
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the average of% D2O for the six time points (10 s, 30 s, 60 s, 300 s, 900 s, and 3600 s) and the differ-
ence in average% D2O values between the apo and liganded states is presented as a heat map with
a color code given at the bottom of each figure (warm colors for deprotection and cool colors for
protection) and colored only if they show a>5% difference (less or more protection) between the
two states and if atleast two time points show a statistically significant difference in a paired two-
tailed student’s t-test (p<0.05). Grey color represents no significant change (0–5%) between the two
states. The exchange at the first two residues for any given peptide is rapid and is ignored in the cal-
culations. Each peptide bar in the heat map view displays the average D% D2O values with its associ-
ated standard deviation and the charge state shown in parentheses.
X-ray crystallographic analysis of the D538G ERa LBD
Generation and production of the D538G ERa LBD mutant
Quick Change Mutagenesis (New England Biolabs, Ipswitch, MA) was performed to change aspar-
tate 538 to glycine on a pGM6 containing the gene for the 6His-Tobacco etch virus (TEV)-ERa
LBD. The following oligonucleotide primers were used to generate the mutant:
Forward: (5’GGTGCCCCTCTACGGCCTGCTGCTGG3’)
Reverse: (5’CCAGCAGCAGGCCGTAGAGGGGCACC3’)
The sequence for the resulting ERa LBD D538G mutant was verified by DNA sequencing.
Protein expression for crystal generation
A 250 mL LB broth containing 100 mg/mL ampicillin was inoculated with a single colony of the E. coli
expression strain BL21 (DE3) transformed with pGM6-ERa LBD D538G mutant. Following overnight
incubation at 37˚C, 101L LB broth containing 100 mg/mL ampicillin were each inoculated with 5-mL
aliquots of the overnight culture. Cells grew at 37˚C with shaking at 180 rpm until they reached mid-
log phase growth (OD600 = 0.8) at which point expression of the protein was induced with 0.3 mM
IPTG and incubation continued overnight with shaking at 20˚C. Cells were harvested by centrifuga-
tion at 3500 g for 30 min, and the pellet was frozen at -20˚C. The pellet was resuspended in 200 mL
BPER and 100 mg DNAse, protein inhibitor cocktail, and lysozyme were added to the lysate. Follow-
ing 30 min of stirring at 4˚C, the lysed cells were centrifuged at 22,000 g for 30 min and the superna-
tant isolated. The soluble fraction was incubated with 2 mL of pre-washed Ni-NTA resin
(ThermoFisher, Grand Island, NY) then placed onto a column. The column was washed with 10 col-
umn volumes of buffer containing 20 mM Tris pH 8.0, 500 mM NaCl, 40 mM imidazole pH 8.0, 10%
glycerol, and 15 mM 2-mercaptoethanol, and the protein was subsequently eluted from the column
using a buffer containing 20 mM Tris pH 8.0, 500 mM NaCl, 500 mM imidazole pH 8.0, 10% glycerol,
and 15 mM 2-mercaptoethanol. The 6His-TEV tag was removed using a 15:1 w/w ratio of LBD to
TEV protease. The LBD was isolated from the tag by a pass over a column containing 2 mL of
washed Ni-NTA resin and the flow through, containing the LBD, was isolated. The protein was dia-
lyzed overnight in a buffer containing 20 mM Tris pH 8.0, 20 mM NaCl, 10% glycerol, and 15 mM 2-
mercaptoethanol then subjected to a final purification on a Resource Q ion exchange column (Ther-
moFisher, Grand Island, NY). A 100 mL linear gradient was used to elute the protein with a buffer
containing 20 mM Tris pH 8.0, 500 mM NaCl, 10% glycerol, and 15 mM 2-mercaptoethanol. A single
peak corresponding to the ERa LBD D538G mutant was isolated and a single band was observed on
a SDS-PAGE gel (BioRad, Hercules, CA). Lastly, the LBD was concentrated to 10 mg/mL using a spin
concentrator, separated into 100-mL aliquots, flash frozen, and stored at -80˚C until use.
Crystallization of the ERa LBD D538G mutant
For the estradiol (E2) and 4-hydroxytamoxifen (TOT)-bound structures, the purified ERa LBD D538G
mutant at 10 mg/mL was incubated for overnight with 1 mM ligand. For the apo D538G and E2
structures, a 2.5-fold mol:mol (excess) of glucocorticoid receptor interacting protein NR box II pep-
tide (GRIP) was incubated with the LBD for approximately 3 hr. Hanging drop method was used for
all crystals using VDX pre-greased plates (Hampton Research, Aliso Viejo, CA). For the apo D538G
structure, 15 mM MgCl2 and 10 mM ATP were added to the protein prior to plating. A total of 1 mL
of 5 mg/mL apo D538G was mixed with 1 mL of 30% PEG 3350, 200 mM MgCl2, and 100 mM Tris
pH 8.5. For the E2-complex structure a total of 1 mL of 5 mg/mL protein was mixed with 1 mL of 25%
PEG 3,350, 200 mM MgCl2, 100 mM Tris pH 8.5, and 1 mM phenylalanine. For the D538G-TOT
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complex structure, the protein/ligand was centrifuged at 19000 g to remove precipitate then 2 mL at
10 mg/mL was mixed with 2 mL of 400 mM ammonium sulfate, 100 mM Tris pH 8.0, and 10% glyc-
erol. For the apo and E2-bound structures, clear triangular rods appeared after 3 days. For the TOT-
bound structure, clear rectangular rods appeared overnight. Paratone-N was used as the cryo-pro-
tectant for the apo and TOT-bound structures, whereas 25% glycerol was used as the cryo-protec-
tant for the E2-bound structure. All x-ray data sets were collected at the Advanced Photon Source at
Argonne National Laboratories, Argonne, Illinois. The TOT-complex data set was collected at the
SBC 19-BM beamline (0.97 A˚), the E2-bound structure at LS-CAT 21-ID-D (0.97 A˚), and the apo
structure at LS-CAT 21-ID-F (0.97 A˚).
X-ray structure solution
Data were indexed, scaled and merged using HKL-3000(Otwinowski and Minor, 1997). Phaser was
used for all molecular replacements (McCoy et al., 2007). An existing structure of the WT ERa LBD
in complex with TOT (PDB: 3ERT) was modified by removing all ligands and water molecules, and
then used as the search molecule for the D538G-TOT structure (Shiau et al., 1998). For the WT and
apo D538G structures, an existing WT ERa LBD-agonist structure (PDB: 2QXM) was modified by
removing all ligands and water molecules, and then used as the search molecule (Nettles et al.,
2008). For the apo and E2-bound structures, one dimer was found in the asymmetric unit (ASU),
whereas four dimers were found for the TOT-bound structure. The CCP4i (Refmac) program suite
was used for all refinement (Winn et al., 2011). The models were refined using iterative rounds of
Refmac and Coot. Densities for the ligands were clearly visible after the first round of refinement for
both the E2- and TOT-bound structures. Unresolved residues were not included in the structures
deposited in the Protein Data Bank including the apo D538G (PDB: 4Q13), D538G-E2 complex
(PDB: 4PXM), and D538G-4OHT (PDB: 4Q50) structures. All x-ray crystal structure images were
made using Pymol.
Molecular dynamics simulations of D538G
Structure preparation
Atomistic molecular models of dimeric ERa were constructed in silico starting from an x-ray crystal
structure of ERa in complex with E2 and a coactivator peptide ( Atomic coordinates were down-
loaded from the Protein Data Bank (PDB code: 1GWR) (Wa¨rnmark et al., 2002)and prepared using
a combination of the MOE (Molecular Operating Environment, 2014) and VMD (Visual Molecular
Dynamics; Humphrey et al., 1996). Using the Structure Preparation module within MOE, all missing
loops were constructed, explicit hydrogen atoms added, a side-chain rotamer search was per-
formed, and protonation states were computed for all titratable residues. The resulting structure
was loaded into VMD, where each protein monomer, coactivator peptide, and all crystallographic
water molecules were written to separate PDB files; the E2 ligand coordinates were discarded for
simulated apo structures. Each histidine residue was renamed according to the CHARMM naming
convention to reflect the computed protonation states, as shown in Table 4. The dimeric ERa struc-
ture was then constructed from the separate PDB files using the PSFGen plugin within VMD. The N-
and C-termini were capped with neutral acetyl and N-methylamido groups, respectively. The protein
complex was subsequently solvated using the Solvate plugin of VMD with a 20-A˚ padding thickness
on all sides, and ions were added using the Autoionize plugin to neutralize the system and yield a
final NaCl concentration of 0.1 M. Ions were placed a minimum distance of 5 A˚ from the protein sur-
face. The resulting fully solvated system contained ~101k atoms. The D538G mutant structure was
constructed in an analogous manner, differing only in an additional mutate’ command in PSFGen to
create the D538G mutation. Additional steps to minimize and equilibrate the mutated region are
discussed below.
Simulations
All MD simulations were performed using the NAMD2 software package (Phillips et al., 2005). The
CHARMM36 force field was used to describe the protein, solvent, and ions, and included CMAP
backbone corrections and NBFIX terms for protein-ion interactions (Mackerell et al., 1998; Macker-
ell, 2004). The TIP3P water model was used to as the explicit solvent (Jorgensen et al., 1983).
Ligand parameters for E2 were taken from the CHARMM General Force Field
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(CGenFF; Vanommeslaeghe and MacKerell, 2012) as assigned by analogy using the
ParamChem (Vanommeslaeghe and MacKerell, 2012) webserver. Attempts to further refine torsion
parameters with moderate penalty scores using the Force Field Toolkit (ffTk; Mayne et al., 2013)
did not yield significant improvement of the potential energy surface. Simulations were performed
under an NPT ensemble at 1.0 atm and 310 K, employing a Nose´-Hoover thermostat and a Langevin
piston with a period of 100 fs, decay of 50 fs, and damping coefficient of 0.5 ps-1 (Martyna et al.,
1994; Feller et al., 1995). A simulation time step of 2 fs was used, and atomic coordinates were
recorded every 500 steps (1 ps). The molecular system employed periodic boundary conditions, and
non-bonded interactions were truncated using a switching function from 10.0 to 12.0 A˚. Long-range
electrostatics were evaluated using the particle mesh Ewald (PME) method (Darden et al., 1993).
Bonded and non-bonded forces were computed at every time step, while PME forces were com-
puted every other time step.
All molecular systems were first simulated to equilibrate ’non-natural’ components of the system
by applying harmonic restraints (k = 1 kcal/mol/A˚2) on heavy atoms present in the 1GWR x-ray crys-
tal structure. Atoms belonging to added water, ions, missing loops (± 2 residues), or mutated resi-
dues (± 2 residues) were left unrestrained. The system was subjected to a 10000-step downhill
minimization, followed by 1 ns of simulation. All restraints were then released, and the system was
simulated for an additional 100 ns of production simulation.
MD simulation trajectory analysis
All analyses were performed using VMD (Humphrey et al., 1996). Simulation trajectories were first
prepared by removing water molecules, concatenating sequential trajectory files, downsampling the
framerate to 10 ps/frame, and rewrapping the periodic system to move the protein center of mass
to the center of the periodic cell. Prior to analysis, all trajectories were aligned to the initial frame by
fitting Ca atoms of the protein, excluding the coactivator peptides from the fit measurement. When
a consistent reference frame was required for cross-trajectory comparisons, all frames were aligned
to the 1GWR x-ray structure prior to analysis. With the exception of explicit time series measure-
ments (i.e. SASA), all other analyses were performed for the last 50 ns of the 100-ns production
simulation.
Side-chain conformations of residue Y537 were visualized by superimposing the position of the
phenolic oxygen every 100 ps (n = 500) using the standard ’points’ representation of VMD. Density
maps of side chain and backbone atoms were computed using the Volmap plugin of VMD with a res-
olution of 1 A˚ and averaging the mass-weighted density over the trajectory. The volumetric maps for
visualizing the side-chain positions were set to the 0.75 isosurface, representing the volume contain-
ing atomic density for greater than 75% of the analyzed trajectory. Ramachandran analysis was per-
formed by measuring the j and y dihedral angles for each residue at a 10-ps interval (n = 5000).
Table 4. Protonation states of histidines for the structure used in MD simulations.
HIS residue number Monomer A Monomer B
356 HSE HSD
373 HSD HSE
377 HSE HSD
398 HSP HSP
474 HSE HSE
476 HSE HSE
488 HSE HSE
501 HSD HSE
513 HSD HSD
516 HSE HSE
524 HSE HSE
547 HSE HSE
DOI: 10.7554/eLife.12792.036
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The data were then converted to a two-dimensional histogram and plotted using the Matplotlib
package of the python programming language (Hunter, 2007). A Gaussian filter was used to smooth
the data (s = 10.0), and the resulting bins were grouped into 10 contours. The lowest intensity con-
tour (background, dark blue) was removed for clarity. The solvent accessible surface area (SASA) was
computed for the side chains of hydrophobic residues 533–536 using the built-in measure sasa func-
tion of VMD. The default probe radius of 1.4 A˚ was used while taking the surrounding protein envi-
ronment into account. SASA measurements were computed at 10-ps intervals (n = 10000) over the
entire production simulation and smoothed using a Gaussian-weighed running average (s = 10.0).
Molecular dynamics simulations of Y537S-TOT complex
A parameter set was constructed for TOT. Its structure was optimized quantum mechanically at the
level of restricted Hartree-Fock (RHF) 6-31g* using the computer program Gaussian 03 (Gaussian 03,
Revision C.02, Frisch et al., 2004). The partial atomic charges of TOT were then derived with
Restrained ElectroStatic Potential (RESP) (Bayly et al., 1993; Cornell et al., 1993) fitting to the
quantum mechanical RHF/6-31g* potential. The ideal geometry was defined as the optimized. The
other molecular mechanical parameters were derived by assigning CHARMm22 atom types for TOT
(Momany and Rone, 1992).
The dimer with the least missing residues of the H11-H12 loop was selected from the D538G-TOT
crystal structure and served as the template structure to model the Y537S-TOT dimer structure. The
side-chain atoms at positions 537 and 538 were removed, and then desired side-chain atoms were
placed with the other missing atoms using the default geometry parameters in CHARMm22. Hydro-
gen atoms were placed with the hbuild module of the computer program CHARMM (Bru¨nger and
Karplus, 1988; Vanommeslaeghe and MacKerell, 2012). Missing residues (loops) in the starting
crystal structure were optimized in three rounds (100 steps of the steepest descent method followed
by two rounds of 100 steps of the adopted New-Raphson method) with updated harmonic con-
straints on the other atoms. Then, all newly added atoms’ positions were optimized in the same
fashion.
The resulting minimized structure was solvated with water molecules of 15 A˚ padding thickness
from the molecular boundary and ionized to reach charge neutrality and the concentration of 0.145
M, both of which were done with VMD (Humphrey et al., 1996). The system was minimized for
5000 steps before a 100-ns MD simulation using NAMD2 (Phillips et al., 2005) was performed.
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